Cargando…
Pharmacogenomics (PGx) Patient with Mixed Levels of Actionable Variant Evidence
OBJECTIVE: To demonstrate the types of clinical recommendations a pharmacogenomics pharmacist may make to medical clinicians with regard to medication management to improve therapeutic outcomes based on varied levels of medical literature evidence. SUMMARY: This case demonstrates how a common type o...
Autores principales: | Schuh, Michael J., Crosby, Sheena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
University of Minnesota Libraries Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051925/ https://www.ncbi.nlm.nih.gov/pubmed/34007616 http://dx.doi.org/10.24926/iip.v11i2.3228 |
Ejemplares similares
-
Additional Utility of Pharmacogenomics (PGx) Panel Testing in a CYP2D6 Normal Metabolizer with a History of Breast Cancer
por: Schuh, Michael J.
Publicado: (2019) -
Pharmacogenomic (PGx) Counseling: Exploring Participant Questions about PGx Test Results
por: Schmidlen, Tara, et al.
Publicado: (2020) -
Pharmacogenomics Testing Confirmation of Carbamazepine Induced DRESS Reaction of an HLA-A*31:01 Positive, Polypharmacy Patient
por: Speicher, Leigh, et al.
Publicado: (2021) -
Potential Benefits of Pre-emptive PGx Testing in Male Breast Cancer Patients
por: Randles, Heather H., et al.
Publicado: (2019) -
Editorial: Population Pharmacogenomics (PGx): From Variant Identification to Clinical Implementation
por: Hiratsuka, Masahiro, et al.
Publicado: (2021)